Program
JNJ-86974680
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Prostatic Neoplasms, led by Johnson & Johnson.
Furthest: phase 1, since Oct 31, 20232 company-led studies, 2 open or runningNext primary completion: Jan 7, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnson | 22 open or running | phase 1since Oct 31, 2023 | Oct 31, 2023 | Jan 7, 2027phase 1 · NCT07319871 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 31, 2023First study: phase 1 study in Carcinoma, Non-Small-Cell LungFirst studyNCT06116786 · 67 enrolled · United States, Germany, South Korea and more
- Dec 22, 2025Phase 1 study in Prostatic NeoplasmsNCT07319871 · 40 planned · United States, United Kingdom
Ahead
- Jan 7, 2027Primary completion: phase 1 study in Prostatic NeoplasmsNCT07319871
- Apr 14, 2027Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungNCT06116786
TargetBeta
ADORA2A →read by rule
“An immune checkpoint inhibitor and antagonist of the adenosine A2A receptor (A2AR; ADORA2A), ”NCIt, by rule
Other programs on ADORA2A
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Caffeinerule | Boehringer Ingelheim | phase 4 | 30 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07319871Prostatic Neoplasms · United States, United Kingdom | 1 | Recruiting | Jan 7, 2027 | 40 |
| NCT06116786Carcinoma, Non-Small-Cell Lung · United States, Germany, South Korea and more | 1 | Active, not recruiting | Apr 14, 2027 | 67 |
How it is read
Names in the registry
- “JNJ-86974680”, 2 entries
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 1 study
- Prostatic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.